Literature DB >> 36271193

Treatment Intensity, Prescribing Patterns, and Blood Pressure Control in Rural Black Patients with Uncontrolled Hypertension.

Doyle M Cummings1, Alyssa Adams2, Shivajirao Patil2, Andrea Cherrington3, Jacqueline R Halladay4, Suzanne Oparil3, Orysya Soroka5, Joanna Bryan Ringel5, Monika M Safford5.   

Abstract

BACKGROUND/
OBJECTIVE: Because racial disparities in hypertension treatment persist, the objective of the present study was to examine patient vs. practice characteristics that influence antihypertensive selection and treatment intensity for non-Hispanic Black (hereafter "Black") patients with uncontrolled hypertension in the rural southeastern USA.
METHODS: We enrolled 25 Black patients from each of 69 rural practices in Alabama and North Carolina with uncontrolled hypertension (systolic blood pressure (BP) ≥ 140 mm Hg) in a 4-arm cluster randomized trial of BP control interventions. Patients' antihypertensive medications were abstracted from medical records and reconciled at the baseline visit. Treatment intensity was computed using the defined daily dose (DDD) method of the World Health Organization. Correlates of greater antihypertensive medication intensity were assessed by linear regression modeling, and antihypertensive medication classes were compared by baseline systolic BP (SBP) level.
RESULTS: A total of 1431 patients were enrolled and had complete baseline data. Antihypertensive treatment intensity averaged 3.7 ± 2.6 equivalent medications at usual dosages and was significantly related to higher baseline systolic BP, older age, male sex, insurance availability, higher BMI, and concurrent diabetes, but not to practice type or medication barriers in regression models. Renin-angiotensin system inhibitors were the most commonly used medications, followed by diuretics and calcium channel blockers. CONCLUSION/RELEVANCE: Antihypertensive treatment intensity for Black patients in the rural southeastern USA with a history of uncontrolled hypertension averaged the equivalent of almost four medications at usual dosages and was significantly associated with baseline SBP levels and other patient characteristics, but not clinic type. TRIAL REGISTRATION: ClinicalTrials.gov NCT02866669.
© 2022. W. Montague Cobb-NMA Health Institute.

Entities:  

Keywords:  Hypertension control; Racial disparities; Treatment intensity

Year:  2022        PMID: 36271193     DOI: 10.1007/s40615-022-01431-2

Source DB:  PubMed          Journal:  J Racial Ethn Health Disparities        ISSN: 2196-8837


  12 in total

1.  Management of high blood pressure in Blacks: an update of the International Society on Hypertension in Blacks consensus statement.

Authors:  John M Flack; Domenic A Sica; George Bakris; Angela L Brown; Keith C Ferdinand; Richard H Grimm; W Dallas Hall; Wendell E Jones; David S Kountz; Janice P Lea; Samar Nasser; Shawna D Nesbitt; Elijah Saunders; Margaret Scisney-Matlock; Kenneth A Jamerson
Journal:  Hypertension       Date:  2010-10-04       Impact factor: 10.190

2.  Defined daily dose (DDD) and its potential use in clinical trials of resistant hypertension.

Authors:  Rodrigo Modolo; Ana Paula de Faria; Alessandra M V Ritter; Antonio Coca; Heitor Moreno
Journal:  Int J Cardiol       Date:  2015-09-28       Impact factor: 4.164

3.  Outcomes in hypertensive black and nonblack patients treated with chlorthalidone, amlodipine, and lisinopril.

Authors:  Jackson T Wright; J Kay Dunn; Jeffrey A Cutler; Barry R Davis; William C Cushman; Charles E Ford; L Julian Haywood; Frans H H Leenen; Karen L Margolis; Vasilios Papademetriou; Jeffrey L Probstfield; Paul K Whelton; Gabriel B Habib
Journal:  JAMA       Date:  2005-04-06       Impact factor: 56.272

4.  Estimating African American admixture proportions by use of population-specific alleles.

Authors:  E J Parra; A Marcini; J Akey; J Martinson; M A Batzer; R Cooper; T Forrester; D B Allison; R Deka; R E Ferrell; M D Shriver
Journal:  Am J Hum Genet       Date:  1998-12       Impact factor: 11.025

5.  2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8).

Authors:  Paul A James; Suzanne Oparil; Barry L Carter; William C Cushman; Cheryl Dennison-Himmelfarb; Joel Handler; Daniel T Lackland; Michael L LeFevre; Thomas D MacKenzie; Olugbenga Ogedegbe; Sidney C Smith; Laura P Svetkey; Sandra J Taler; Raymond R Townsend; Jackson T Wright; Andrew S Narva; Eduardo Ortiz
Journal:  JAMA       Date:  2014-02-05       Impact factor: 56.272

6.  Multiple Social Vulnerabilities to Health Disparities and Hypertension and Death in the REGARDS Study.

Authors:  Jordan B King; Laura C Pinheiro; Joanna Bryan Ringel; Adam P Bress; Daichi Shimbo; Paul Muntner; Kristi Reynolds; Mary Cushman; George Howard; Jennifer J Manly; Monika M Safford
Journal:  Hypertension       Date:  2021-11-17       Impact factor: 10.190

Review 7.  Social determinants of hypertension in high-income countries: A narrative literature review and future directions.

Authors:  Atsushi Nakagomi; Yuichi Yasufuku; Takayuki Ueno; Katsunori Kondo
Journal:  Hypertens Res       Date:  2022-07-20       Impact factor: 5.528

Review 8.  Hypertension Treatment in Blacks: Discussion of the U.S. Clinical Practice Guidelines.

Authors:  Stephen K Williams; Joseph Ravenell; Sara Seyedali; Sam Nayef; Gbenga Ogedegbe
Journal:  Prog Cardiovasc Dis       Date:  2016-09-29       Impact factor: 8.194

9.  Associations Between Social Determinants and Hypertension, Stage 2 Hypertension, and Controlled Blood Pressure Among Men and Women in the United States.

Authors:  Yvonne Commodore-Mensah; Ruth-Alma Turkson-Ocran; Kathryn Foti; Lisa A Cooper; Cheryl Dennison Himmelfarb
Journal:  Am J Hypertens       Date:  2021-08-09       Impact factor: 3.080

10.  Characteristics and treatment of African-American and European-American patients with resistant hypertension identified using the electronic health record in an academic health centre: a case-control study.

Authors:  Megan M Shuey; Jocelyn S Gandelman; Cecilia P Chung; Hui Nian; Chang Yu; Joshua C Denny; Nancy J Brown
Journal:  BMJ Open       Date:  2018-06-27       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.